---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-089108"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2024-10-21T23:59:59+00:00"
generated_at: "2026-05-30T12:26:42.310299+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CERo submits complete response letter to FDA clinical hold for CERO-1236; clinic entry now expected early 2025

## Summary
- Submitted complete response to FDA clinical hold on CERO-1236; 30-day review cycle expected.
- Adjusted clinical trial entry from 2024 to early 2025 based on FDA timeline.
- Cash balance of $3.2M as of Sept 30, 2024, sufficient for near-term strategy execution.
- Al Kucharchuk appointed CFO; Kristen Pierce promoted to Chief Development Officer.
- Board of Directors changes made to enhance business plan execution.

## SEC filing metadata
- accession: 0001213900-24-089108
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2024-10-21T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390024089108/0001213900-24-089108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390024089108/ea021808801-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-089108
- JSON: https://secwatch.observer/filing/0001213900-24-089108.json
- Plain text: https://secwatch.observer/filing/0001213900-24-089108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.